RecruitingNCT04943588

Treating Hepatitis C in Pakistan. Strategies to Avoid Resistance to Antiviral Drugs

Sponsor

Queen Mary University of London

Enrollment

25,000 participants

Start Date

Nov 1, 2021

Study Type

OBSERVATIONAL

Conditions

Hepatitis C, Chronic

Summary

We will determine how best to manage the hepatitis C virus (HCV) epidemic in Pakistan by measuring effectiveness of Pakistan-government sponsored current therapies, emergence of viral resistance, consequences of infection (chiefly liver cancer) and through developing models, based on incidence data, determine the proportion of people who need curative treatment to eliminate HCV, and assess whether targeting can optimise this.

Eligibility

Min Age: 18 YearsMax Age: 100 Years

Plain Language Summary

Simplified for easier understanding

This study in Pakistan tests different strategies for treating hepatitis C infection while trying to prevent the virus from developing resistance to the antiviral medications used. **You may be eligible if...** - You are an adult (18 or older) - You are willing to be tested for hepatitis C - You are a resident of the area and do not plan to leave the region - You are willing to return for a follow-up test in 12 months **You may NOT be eligible if...** - You are unwilling to give consent or undergo necessary tests - You have a serious illness (other than hepatitis C) that could interfere with treatment - Your life expectancy is less than 12 months - You are unwilling to follow the study protocol Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.